Effectiveness and side effects of fingolimod in 3-year follow-up of patients with relapsing- remitting multiple sclerosis(RRMS)

Vice chancellor for research, Kermanshah University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新: 2018年2月22日

试验速览

暂无简介。

•Age 18-45 years; EDSS score between 0 and 5.5; At least one relapse in the previous year despite treatment with a variety of first-line DMT; At least two relapses in the past two years despite treatment with a variety of first-line DMT; No relapse in the 30 days before starting treatment with fingolimod; Negative pregnancy test for women of childbearing age.
•Exclusion criteria: macular edema at baseline;
•acute or chronic active bacterial infection, fungal or Viral; Treatment with intravenous corticosteroids within 30 days prior to the start fingolimod; History of treatment with cyclophosphamide or mitoxantrone at any time; Breastfeeding and pregnancy;AST and ALT more than double upper limit of normal; Full or direct bilirubin greater than the upper limit of normal; Creatinine more than 1.7 mg per deciliter; White blood cells below 3500 per cubic millimeter; Lymphocyte count below 800 per cubic millimeter; The presence of uveitis

发起方

Vice chancellor for research, Kermanshah University of Medical Sciences